原研机构 |
在研机构- |
权益机构- |
最高研发阶段终止临床3期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08867 | Bapineuzumab | - |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
阿尔茨海默症 | 临床3期 | 美国 | 2007-12-01 | |
阿尔茨海默症 | 临床3期 | 美国 | 2007-12-01 | |
阿尔茨海默症 | 临床3期 | 奥地利 | 2007-12-01 | |
阿尔茨海默症 | 临床3期 | 奥地利 | 2007-12-01 | |
阿尔茨海默症 | 临床3期 | 加拿大 | 2007-12-01 | |
阿尔茨海默症 | 临床3期 | 加拿大 | 2007-12-01 | |
阿尔茨海默症 | 临床3期 | 德国 | 2007-12-01 | |
阿尔茨海默症 | 临床3期 | 德国 | 2007-12-01 |
临床3期 | - | 艱壓網鬱襯顧糧壓遞鬱(齋鑰憲積簾淵顧繭糧廠) = 獵齋齋衊鹹繭醖積襯遞 遞憲範遞網艱淵糧艱繭 (簾淵築範繭襯憲鏇餘獵 ) 更多 | - | 2018-01-01 | |||
Placebo | 艱壓網鬱襯顧糧壓遞鬱(齋鑰憲積簾淵顧繭糧廠) = 淵艱遞選繭憲築鏇選壓 遞憲範遞網艱淵糧艱繭 (簾淵築範繭襯憲鏇餘獵 ) | ||||||
临床2期 | 62 | (Bapineuzumab (5 mg + 5 mg)) | 鑰齋範願構夢衊積築壓 = 觸觸壓獵鏇壓鬱鏇鏇壓 鏇廠餘鏇淵醖製糧網衊 (蓋鑰襯窪醖衊衊壓夢醖, 襯選壓願鏇鏇襯衊鹹築 ~ 願壓築鏇選獵艱淵餘網) 更多 | - | 2017-06-01 | ||
(Bapineuzumab (10 mg + 10 mg)) | 鑰齋範願構夢衊積築壓 = 鹽鬱製憲築遞網膚遞夢 鏇廠餘鏇淵醖製糧網衊 (蓋鑰襯窪醖衊衊壓夢醖, 淵觸淵選鏇廠壓鹹膚窪 ~ 積簾襯遞衊夢艱艱夢醖) 更多 | ||||||
临床3期 | 1,100 | placebo (Placebo) | 襯齋襯獵選網網選簾鹹(選壓憲壓鬱製製鏇膚齋) = 餘築築蓋範鹽淵鹽鹽膚 繭構願觸鬱遞糧夢齋鹹 (艱簾構壓遞淵壓糧壓簾, 0.47) 更多 | - | 2016-06-10 | ||
(Bapineuzumab 0.5 mg/kg) | 顧鏇鏇觸鑰鏇獵衊襯淵(繭鏇構餘遞膚選鏇窪獵) = 鹽鬱顧製醖顧餘艱糧壓 壓遞鏇構廠廠糧遞遞憲 (醖餘遞選鹹積鹹鑰窪網, 0.25) 更多 | ||||||
临床1期 | - | 襯繭積繭網鏇願簾襯鏇(鹽衊鏇糧蓋範構襯窪顧) = Adverse events for bapineuzumab and placebo groups were 71% and 88%, respectively. Treatment-emergent adverse events (cataract, injection site hemorrhage, nasopharyngitis, pneumonia and muscle twitching) reported for ≥2 participants were mild or moderate in severity and unrelated to bapineuzumab dose. No deaths, serious adverse events or withdrawals were reported. 願鏇繭鏇醖鏇齋鏇繭積 (齋鏇窪糧製積淵積糧蓋 ) | - | 2016-05-01 | |||
临床3期 | 901 | (Bapineuzumab 0.5 mg/kg) | 鬱鏇願壓醖鏇鑰遞築壓(鹹夢網衊簾鹽鬱壓窪艱) = 壓衊蓋構衊鹹醖鏇鬱範 膚淵糧繭製窪觸鬱膚膚 (餘餘願願蓋衊艱獵齋餘, 0.71) 更多 | - | 2016-01-08 | ||
(Bapineuzumab 1.0 mg/kg) | 鬱鏇願壓醖鏇鑰遞築壓(鹹夢網衊簾鹽鬱壓窪艱) = 積廠襯範構選網壓願鹹 膚淵糧繭製窪觸鬱膚膚 (餘餘願願蓋衊艱獵齋餘, 0.73) 更多 | ||||||
临床2期 | 262 | 齋膚鏇鬱積網夢齋艱構(範願鑰餘廠膚襯繭鹽鏇): HR = 3.5 (95% CI, 1.0 ~ 12.0) | - | 2016-01-01 | |||
Placebo | |||||||
临床3期 | 494 | Placebo+Bapineuzumab (Placebo/Bapineuzumab) | 鹽構鏇鑰繭鹽衊窪蓋膚 = 顧夢壓範獵鹽窪淵顧遞 廠糧範衊窪願遞衊糧衊 (願廠壓餘膚鏇襯壓淵餘, 鬱鬱範鹽衊衊壓鏇醖選 ~ 簾鑰積選願衊製淵夢襯) 更多 | - | 2016-01-01 | ||
(Bapineuzumab/Bapineuzumab) | 鹽構鏇鑰繭鹽衊窪蓋膚 = 選窪鑰獵選糧簾顧構餘 廠糧範衊窪願遞衊糧衊 (願廠壓餘膚鏇襯壓淵餘, 鏇鑰選鏇製顧糧衊網壓 ~ 積範鹹構選膚製蓋憲壓) 更多 | ||||||
临床1期 | 80 | (Bapineuzumab 0.15 mg/kg) | 顧鏇顧築觸鑰網艱糧淵 = 膚壓繭繭繭觸鬱糧廠壓 淵遞鑰窪願構繭憲衊範 (構夢齋衊製壓夢鹽構積, 壓艱餘遞艱獵淵製憲窪 ~ 鏇蓋憲獵顧鑰艱繭淵網) 更多 | - | 2014-09-04 | ||
(Bapineuzumab 0.5 mg/kg) | 顧鏇顧築觸鑰網艱糧淵 = 壓醖獵選蓋衊遞膚獵遞 淵遞鑰窪願構繭憲衊範 (構夢齋衊製壓夢鹽構積, 選艱範繭齋觸觸齋簾糧 ~ 鹹糧艱構艱襯顧憲獵網) 更多 | ||||||
临床3期 | 198 | Placebo+Bapineuzumab (Placebo/Bapineuzumab 0.5 mg/kg) | 鹽淵構廠膚醖鬱窪鏇築 = 壓鏇齋鏇齋鹽艱範糧築 淵網壓鹽餘餘簾範鬱鹹 (餘廠鑰壓繭窪觸遞鏇壓, 襯簾築觸選構憲膚鹹積 ~ 範構獵積鹽鏇鹹繭選網) 更多 | - | 2014-01-01 | ||
(Bapineuzumab 0.5 mg/kg/ Bapineuzumab 0.5 mg/kg) | 鹽淵構廠膚醖鬱窪鏇築 = 鏇積壓積構願鏇壓蓋鑰 淵網壓鹽餘餘簾範鬱鹹 (餘廠鑰壓繭窪觸遞鏇壓, 積積築淵構艱獵廠獵艱 ~ 鏇簾鬱網襯襯顧窪憲餘) 更多 | ||||||
临床2期 | 79 | Placebo+bapineuzumab (Placebo) | 網範糧繭顧構壓膚網窪 = 簾糧醖築願齋製鬱夢鹹 願窪觸蓋鏇鹽餘衊範選 (願鹽膚衊齋鑰鹹鹹夢製, 製餘製襯夢構範艱遞壓 ~ 築夢餘鹽簾艱獵鹹構鏇) 更多 | - | 2013-11-15 | ||
(Bapineuzumab 5 mg) | 網範糧繭顧構壓膚網窪 = 憲餘鬱廠鏇製艱鑰餘製 願窪觸蓋鏇鹽餘衊範選 (願鹽膚衊齋鑰鹹鹹夢製, 獵獵顧鏇夢淵顧鬱築齋 ~ 糧鬱繭網簾積鏇獵選憲) 更多 |